To the full analysis
OrthoPediatrics stock: growth
KIDSOrthoPediatrics reported $236.35M in revenue for fiscal 2025, up 15.4% on the prior year, up 27.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
23.3%
per year from 2014 to 2025, per share 11%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2014 | |
|---|---|---|---|
| Revenue | 27.2% | 22.5% | 23.3% |
| Revenue per share | 20.7% | 9.3% | 11.0% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2014 | $23.68M | −$9.55M | −$13.24M |
| 2015 | $31M | −$7.89M | −$3.14M |
| 2016 | $37.3M | −$6.57M | −$5.87M |
| 2017 | $45.62M | −$8.93M | −$13.76M |
| 2018 | $57.56M | −$12.03M | −$21.05M |
| 2019 | $72.55M | −$13.73M | −$29.86M |
| 2020 | $71.08M | −$32.94M | −$29.83M |
| 2021 | $98.05M | −$16.26M | −$29.07M |
| 2022 | $122.29M | $1.26M | −$31.8M |
| 2023 | $148.73M | −$20.97M | −$46.03M |
| 2024 | $204.73M | −$37.82M | −$41.31M |
| 2025 | $236.35M | −$39.65M | −$15.96M |
Revenue by segment
How OrthoPediatrics Corp. makes its money and how that has shifted. Names are as the company reports them.
- Trauma and Deformity70%
- Spine28%
- Sports Medicine And Other2%
- Other< 1%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Trauma and Deformity | $32.8M | $39.7M | $49.37M | $47.68M | $65.83M | $85.06M | $106.78M | $145.13M | $166.3M | 70.4% |
| Spine | $11.59M | $16.66M | $21.49M | $20.74M | $28.05M | $33.43M | $37.93M | $55.15M | $66.05M | 27.9% |
| Sports Medicine And Other | no data | no data | no data | no data | no data | no data | no data | no data | $4M | 1.7% |
| Other | $1.23M | $1.2M | $1.7M | $2.66M | $4.17M | $3.81M | $4.02M | $4.45M | $0 | 0% |
| Total revenue | $45.62M | $57.56M | $72.55M | $71.08M | $98.05M | $122.29M | $148.73M | $204.73M | $236.35M | 100% |
Revenue by region
Where OrthoPediatrics Corp. generates its revenue.
- United States79%
- Outside the US21%
Figures as a table
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| United States | $43.46M | $55.06M | $62.97M | $77.78M | $92.42M | $111.01M | $161.16M | $186.4M | 78.9% |
| Outside the US | $14.1M | $17.5M | $8.11M | $20.27M | $29.87M | $37.72M | $43.56M | $49.95M | 21.1% |
| Total revenue | $57.56M | $72.55M | $71.08M | $98.05M | $122.29M | $148.73M | $204.73M | $236.35M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 29 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.